Big Pharma's Smaller Deals Benefit Biotech Sector
Big Pharma is focusing on smaller acquisitions rather than large megadeals, which is benefiting biotech stocks. The SPDR S&P Biotech ETF has outperformed the S&P 500 this year, and the trend of midsize deals is expected to continue as pharma companies seek to replenish their pipelines.
Topics: Biotech Mergers and Acquisitions Pharmaceuticals Stock Performance